Phase 3 Results for Qilu Pharmaceutical’s Pertuzumab Biosimilar

Results of phase 3 pertuzumab studies comparing Qilu’s QL1209 with Roche’s Perjeta® with trastuzumab and docetaxel were published in the British Journal of Cancer on 21 June 2024.  

The studies demonstrated that QL1209 is equivalent to Perjeta® in safety and efficacy for patients with HER2-positive, ER/PR-negative, early or locally advanced breast cancer. 

QL1209 is reportedly the first pertuzumab biosimilar produced and submitted for approval in China.